Glassia ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
231	α1−アンチトリプシン欠乏症	2

231. α1−アンチトリプシン欠乏症

---

臨床試験数 : 93 /  薬物数 : 77 - (DrugBank : 8) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 36

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03385395 (ClinicalTrials.gov)	July 2018	1/12/2017	Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency	A Randomized, Double-blind, Parallel-group, Multicenter, Pharmacokinetic Study Comparing Weekly Intravenous Administration of OctaAlpha1 (Octapharma) With a Marketed Preparation Glassia® (Kamada Ltd.) in Subjects With Alpha-1-antitrypsin Deficiency	Alpha 1-Antitrypsin Deficiency	Drug: OctaAlpha1;Drug: Glassia	Octapharma	NULL	Withdrawn	18 Years	N/A	All	0	Phase 2	NULL
2	NCT03172455 (ClinicalTrials.gov)	May 1, 2017	29/5/2017	Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)	Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)	Acute-graft-versus-host Disease;Steroid Refractory Acute Graft Versus Host Disease;Graft-versus-host-disease;Graft Vs Host Disease;Alpha 1-Antitrypsin Deficiency;Alpha-1 Proteinase Inhibitor;Alpha-1 Protease Inhibitor Deficiency;Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant	Drug: Glassia	Impatients N.V. trading as myTomorrows	Kamada, Ltd.	No longer available	N/A	N/A	All			NULL